Cargando…
Duration of vaccine effectiveness against SARS-CoV-2 infection, hospitalisation, and death in residents and staff of long-term care facilities in England (VIVALDI): a prospective cohort study
BACKGROUND: Residents and staff in long-term care facilities have been prioritised for vaccination against SARS-CoV-2, but data on potential waning of vaccine effectiveness and the effect of booster doses in this vulnerable population are scarce. We aimed to evaluate effectiveness of one, two, and t...
Autores principales: | Shrotri, Madhumita, Krutikov, Maria, Nacer-Laidi, Hadjer, Azmi, Borscha, Palmer, Tom, Giddings, Rebecca, Fuller, Christopher, Irwin-Singer, Aidan, Baynton, Verity, Tut, Gokhan, Moss, Paul, Hayward, Andrew, Copas, Andrew, Shallcross, Laura |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
The Author(s). Published by Elsevier Ltd.
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9252508/ https://www.ncbi.nlm.nih.gov/pubmed/35813279 http://dx.doi.org/10.1016/S2666-7568(22)00147-7 |
Ejemplares similares
-
Outcomes of SARS-CoV-2 omicron infection in residents of long-term care facilities in England (VIVALDI): a prospective, cohort study
por: Krutikov, Maria, et al.
Publicado: (2022) -
Clinical Effectiveness of SARS-CoV-2 Booster Vaccine Against Omicron Infection in Residents and Staff of Long-term Care Facilities: A Prospective Cohort Study (VIVALDI)
por: Stirrup, Oliver, et al.
Publicado: (2022) -
Prevalence and duration of detectable SARS-CoV-2 nucleocapsid antibodies in staff and residents of long-term care facilities over the first year of the pandemic (VIVALDI study): prospective cohort study in England
por: Krutikov, Maria, et al.
Publicado: (2022) -
Vaccine effectiveness of the first dose of ChAdOx1 nCoV-19 and BNT162b2 against SARS-CoV-2 infection in residents of long-term care facilities in England (VIVALDI): a prospective cohort study
por: Shrotri, Madhumita, et al.
Publicado: (2021) -
Severe Acute Respiratory Syndrome Coronavirus 2 Anti-Spike Antibody Levels Following Second Dose of ChAdOx1 nCov-19 or BNT162b2 Vaccine in Residents of Long-term Care Facilities in England (VIVALDI)
por: Stirrup, Oliver, et al.
Publicado: (2022)